Drug intelligence / Profile preview

DAW2020

Development stage: Phase 2
Lead developer: Brigham and Women's Hospital
Modality: Small Molecules
Administration: Oral

Overview

DAW2020 is a small molecule drug developed by The Brigham & Women's Hospital, Inc. It is primarily indicated for the treatment of **Obstructive Sleep Apnea (OSA)**. DAW2020 acts as a hypnotic, prolonging total sleep time in OSA patients. The mechanism of action is not explicitly detailed in the available information.

Brand names: StratteraAmbien
Other names: warfarin-Brigham and Women's Hospital-obstructive sleep apneaDAW2022DAW-2022DAW 2022atomoxetine + DAW2020

Targets

NET (Norepinephrine Transporter)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)

Beyond the preview

Go deeper on DAW2020.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DAW2020.

Explore the full profile